LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY
批准号:
6679466
负责人:
John Guy
金额:
$29.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-30 至 2007-08-31
关键词:
adeno associated virus group apoptosis biotechnology cell growth regulation cellular pathology disease /disorder etiology disease /disorder model eye fundus photography free radical oxygen gene delivery system gene expression gene mutation gene targeting gene therapy green fluorescent proteins laboratory rat magnetic resonance imaging mitochondrial DNA mitochondrial disease /disorder optic nerve disorder oxidative phosphorylation ribozymes tissue /cell culture transfection /expression vector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): During the previous grant cycle we have made major strides towards determining the pathogenesls and testing a treatment for LHON. First, we discovered that ND4 mutant cells have a severe reduction in ATP synthesis, even though mild reductions in complex I activity appear insufficient to induce disease. Since no technology exists to introduce DNA directly into mitochondria, we overcame this deficiency in oxidative phosphorylation by constructing a "nuclear version" of the mitochondrial gene then targeted the cytoplasmically synthesized protein to the mitochondria by using a targeting sequence appended to the reading frame (allotopic expression). When delivered to cultured cells containing a mutant ND4, respiratory function was restored. Could this also be useful in the treatment of patients? To help answer this we now propose to test our hypothesis that reductions in oxidative phosphorylation and/or reactive oxygen species (ROS) induce optic neuropathy in an animal model system that closely approximates LHON. Our specific aims logically progress from understanding the physiological consequences of a mutated ND4 gene and loss of ND4 expression to creating a novel animal disease model of LHON.
(1) We will test for a recessive negative effect of mutated ND4 protein by allotopic expression of a synthetic mlssense gene that results in the same substitution of an arginine for histidine, at amino acid 340, in the ND4 protein as that produced by the G11778A mutation in mitochondrial DNA. We will allotopically infect cells harboring normal mitochondrial DNA, and then evaluate for cytopathic effects by measuring cell growth, apoptosis, respiration and ROS.
(2) We will investigate the ability of ribozymes designed to reduce expression of the complex I subunit (ND4) most commonly associated with LHON to adversely impact cellular function. We will import the ribozyme into mitochondria by coupling it with an RNA import signal and then evaluate for cytopathic effects in vitro using assays of oxidative phosphorylation, ROS, cell growth and apoptosis.
(3) We will test the ability of the ND4 ribozyme and allotopically expressed mutant ND4 gene to induce optic nerve degeneration. We will deliver them to the mouse visual system individually or together (using a vector expressing both ribozyme and mutant gene), then analyze the mechanism, extent and foci of injury using serial in vivo digital fundus photography, MRI and post-mortem measurements of ganglion cell and axon damage.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Intravenous MitoTargeted AAV9 Gene Therapy for Treatment of Visual Loss and Encephalopathy in Leigh Syndrome and NARP
-
批准号:9218874
-
项目类别:
-
资助金额:$38.38万
-
财政年份:2017
-
负责人:John Guy
-
依托单位:
Leber's Hereditary Optic Neuropathy: Gene Therapy Clinical Trial
-
批准号:8828695
-
项目类别:
-
资助金额:$205.04万
-
财政年份:2014
-
负责人:John Guy
-
依托单位:
Leber's Hereditary Optic Neuropathy: Gene Therapy Clinical Trial
-
批准号:9261541
-
项目类别:
-
资助金额:$116.06万
-
财政年份:2014
-
负责人:John Guy
-
依托单位:
Leber's Hereditary Optic Neuropathy: Gene Therapy Clinical Trial
-
批准号:8675335
-
项目类别:
-
资助金额:$122.31万
-
财政年份:2014
-
负责人:John Guy
-
依托单位:
Leber Hereditary Optic Neuropathy: Gene Therapy Trial
-
批准号:8264769
-
项目类别:
-
资助金额:$93.15万
-
财政年份:2008
-
负责人:John Guy
-
依托单位:
Leber Hereditary Optic Neuropathy: Gene Therapy Trial
-
批准号:8089419
-
项目类别:
-
资助金额:$108.48万
-
财政年份:2008
-
负责人:John Guy
-
依托单位:
Leber Hereditary Optic Neuropathy: Gene Therapy Trial
-
批准号:8144577
-
项目类别:
-
资助金额:$47.3万
-
财政年份:2008
-
负责人:John Guy
-
依托单位:
Leber Hereditary Optic Neuropathy: Gene Therapy Trial
-
批准号:7736225
-
项目类别:
-
资助金额:$87.15万
-
财政年份:2008
-
负责人:John Guy
-
依托单位:
Leber Hereditary Optic Neuropathy: Gene Therapy Trial
-
批准号:7936872
-
项目类别:
-
资助金额:$86.25万
-
财政年份:2008
-
负责人:John Guy
-
依托单位:
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria
-
批准号:7686732
-
项目类别:
-
资助金额:$38.01万
-
财政年份:2007
-
负责人:John Guy
-
依托单位:
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria
-
批准号:7484157
-
项目类别:
-
资助金额:$38.36万
-
财政年份:2007
-
负责人:John Guy
-
依托单位:
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria
-
批准号:8136071
-
项目类别:
-
资助金额:$36.11万
-
财政年份:2007
-
负责人:John Guy
-
依托单位:
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria
-
批准号:7936870
-
项目类别:
-
资助金额:$23.09万
-
财政年份:2007
-
负责人:John Guy
-
依托单位:
Modification of AdenoAssociated Virus to deliver DNA directly to Mitochondria
-
批准号:7266744
-
项目类别:
-
资助金额:$36.63万
-
财政年份:2007
-
负责人:John Guy
-
依托单位:
LEBER HEREDITARY OPTIC NEUROPATHY-- GENE THERAPY
-
批准号:2909251
-
项目类别:
-
资助金额:$34.63万
-
财政年份:1999
-
负责人:John Guy
-
依托单位:
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY
-
批准号:6179055
-
项目类别:
-
资助金额:$34.82万
-
财政年份:1999
-
负责人:John Guy
-
依托单位:
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY
-
批准号:6384776
-
项目类别:
-
资助金额:$35.63万
-
财政年份:1999
-
负责人:John Guy
-
依托单位:
Transgenic Mitomice Models for Treatment of Blinding Diseases
-
批准号:9021653
-
项目类别:
-
资助金额:$38.38万
-
财政年份:1999
-
负责人:John Guy
-
依托单位:
LEBER HEREDITARY OPTIC NEUROPATHY: GENE THERAPY
-
批准号:6942249
-
项目类别:
-
资助金额:$29.1万
-
财政年份:1999
-
负责人:John Guy
-
依托单位:
Transgenic Mitomice Models for Treatment of Blinding Diseases
-
批准号:8617845
-
项目类别:
-
资助金额:$37.61万
-
财政年份:1999
-
负责人:John Guy
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: